An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.

Journal Article (Journal Article;Review)

Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease.

Full Text

Duke Authors

Cited Authors

  • Julander, JG; Demarest, JF; Taylor, R; Gowen, BB; Walling, DM; Mathis, A; Babu, YS

Published Date

  • November 2021

Published In

Volume / Issue

  • 195 /

Start / End Page

  • 105180 -

PubMed ID

  • 34551346

Pubmed Central ID

  • PMC8483777

Electronic International Standard Serial Number (EISSN)

  • 1872-9096

Digital Object Identifier (DOI)

  • 10.1016/j.antiviral.2021.105180


  • eng

Conference Location

  • Netherlands